Intestinal failure–associated liver disease: Current challenges in screening, diagnosis, and parenteral nutrition considerations
Nutrition in Clinical Practice · 2024-10 · 39 (5) · 1003-1025
DOI: 10.1002/ncp.11116 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrition in Clinical Practice, online erschienen am 21.01.2024. Verfasst von Trevor Tabone und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, St James University Hospital, Leeds, United Kingdom. Hauptthemen laut MEDLINE: Parenteral Nutrition, Liver Diseases, Intestinal Failure. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 101 Literaturangaben.
Abstract (Originalsprache)
Intestinal failure–associated liver disease (IFALD) is a serious life‐limiting complication that can occur throughout the clinical course of intestinal failure and its management by parenteral nutrition (PN). Despite this, there is a lack of a standardized definition for IFALD, which makes this insidious condition increasingly difficult to screen and diagnose in clinical practice. Attenuating the progression of liver disease before the onset of liver failure is key to improving morbidity and mortality in these patients. This requires timely detection and promptly addressing reversible factors. Although there are various noninvasive tools available to the clinician to detect early fibrosis or cirrhosis in various chronic liver disease states, these have not been validated in the patient population with IFALD. Such tools include biochemical composite scoring systems for fibrosis, transient elastography, and dynamic liver function tests. This review article aims to highlight the existing real need for an accurate, reproducible method to detect IFALD in its early stages. In addition, we also explore the role PN plays in the pathogenesis of this complex multifactorial condition. Various aspects of PN administration have been implicated in the etiology of IFALD, including the composition of the lipid component, nutrient excess and deficiency, and infusion timing. We aim to highlight the clinical relevance of these PN‐associated factors in the development of IFALD and how these can be managed to mitigate the progression of IFALD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, St James University Hospital, Leeds, United Kingdom.
Zitieren
APA
Tabone, T., Mooney, P., & Donnellan, C. (2024). Intestinal failure–associated liver disease: Current challenges in screening, diagnosis, and parenteral nutrition considerations. Nutrition in Clinical Practice, 39(5), 1003-1025. https://doi.org/10.1002/ncp.11116
Vancouver
Tabone T, Mooney P, Donnellan C. Intestinal failure–associated liver disease: Current challenges in screening, diagnosis, and parenteral nutrition considerations. Nutrition in Clinical Practice. 2024;39(5):1003-1025. doi:10.1002/ncp.11116
BibTeX
@article{Tabone2024,
author = {Tabone, Trevor and Mooney, Peter and Donnellan, Clare},
title = {Intestinal failure–associated liver disease: Current challenges in screening, diagnosis, and parenteral nutrition considerations},
journal = {Nutrition in Clinical Practice},
year = {2024},
volume = {39},
number = {5},
pages = {1003--1025},
doi = {10.1002/ncp.11116}
}
EUVIMED